Post Strict Regulations, Govt Plans To Ease Clinical Trials Norms

Bangalore: Clinical trials in India have seen a drastic fall after stringent norms were introduced following Supreme Court directives. Not only have the number of trial approvals in the country reduced, there has also been a significant reduction in the number of sponsoring Pharma firms applying for such approvals. Recently, during an event, Union health Minister Ghulam Nabi Azad hinted that the government is on the talk for relaxing norms for clinical trials in India, reports Nirmalya Dutta of Health.India.                 

The Union Minister, at an event held in biopharma company Biocon’s facility, said “There has been more than 50 percent drop in clinical trials after stringent regulations were put in place last year. We did it to improve transparency, but that should not happen at the cost of innovation. Industry feels that regulations we have made are too difficult. I think we need to strike a balance, considering the rise in some deadly diseases,” reports Health.India.

Also Read:
India Among The 10 Largest Arms Importers In The World
Socks, Cellphones, Cartons: Innovative Ways To Sneak In Gold?